Success Metrics

Active Trials
3(75%)

Phase Distribution

Ph phase_3
2
50%
Ph early_phase_1
1
25%

Phase Distribution

1

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 3Large-scale testing
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(4)

Detailed Status

Recruiting2
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (33.3%)
Phase 32 (66.7%)

Trials by Status

active_not_recruiting125%
not_yet_recruiting125%
recruiting250%

Recent Activity

3 active trials
Showing 4 of 4
recruitingphase_3

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

NCT06141473
recruitingphase_3

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

NCT06141486
not_yet_recruitingearly_phase_1

ImmunoMRI for Assessment of Tumor-associated Macrophages

NCT07066436
active_not_recruiting

O-RADS MRI System on Early Detection of Ovarian Cancer

NCT07009743

Clinical Trials (4)

Showing 4 of 4 trials
NCT06141473Phase 3

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Recruiting
NCT06141486Phase 3

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

Recruiting
NCT07066436Early Phase 1

ImmunoMRI for Assessment of Tumor-associated Macrophages

Not Yet Recruiting
NCT07009743

O-RADS MRI System on Early Detection of Ovarian Cancer

Active Not Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4